291 related articles for article (PubMed ID: 31554698)
1. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.
Hinz TK; Kleczko EK; Singleton KR; Calhoun J; Marek LA; Kim J; Tan AC; Heasley LE
Mol Pharmacol; 2019 Dec; 96(6):862-870. PubMed ID: 31554698
[TBL] [Abstract][Full Text] [Related]
2. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
4. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA
Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819
[TBL] [Abstract][Full Text] [Related]
5. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
6. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).
Low JL; Lau DP; Zhang X; Kwang XL; Rohatgi N; Chan JV; Chong FT; Wong SQR; Leong HS; Thangavelu MT; Rikka S; Skanderup AMJ; Tan DSW; Periyasamy G; Koh JLY; Iyer NG; DasGupta R
EBioMedicine; 2021 Feb; 64():103220. PubMed ID: 33529999
[TBL] [Abstract][Full Text] [Related]
7. Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models.
Ouyang X; Barling A; Lesch A; Tyner JW; Choonoo G; Zheng C; Jeng S; West TM; Clayburgh D; Courtneidge SA; McWeeney SK; Kulesz-Martin M
Cancer Biol Ther; 2018; 19(10):921-933. PubMed ID: 29856687
[TBL] [Abstract][Full Text] [Related]
8. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
[TBL] [Abstract][Full Text] [Related]
9. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC.
Rong C; Muller MF; Xiang F; Jensen A; Weichert W; Major G; Plinkert PK; Hess J; Affolter A
Br J Cancer; 2020 Jul; 123(2):288-297. PubMed ID: 32424150
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.
Marshall ME; Hinz TK; Kono SA; Singleton KR; Bichon B; Ware KE; Marek L; Frederick BA; Raben D; Heasley LE
Clin Cancer Res; 2011 Aug; 17(15):5016-25. PubMed ID: 21673064
[TBL] [Abstract][Full Text] [Related]
11. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
12. EGFR modulates complement activation in head and neck squamous cell carcinoma.
Abu-Humaidan AHA; Ekblad L; Wennerberg J; Sørensen OE
BMC Cancer; 2020 Feb; 20(1):121. PubMed ID: 32054454
[TBL] [Abstract][Full Text] [Related]
13. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
14. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.
Singleton KR; Kim J; Hinz TK; Marek LA; Casás-Selves M; Hatheway C; Tan AC; DeGregori J; Heasley LE
Mol Pharmacol; 2013 Apr; 83(4):882-93. PubMed ID: 23371912
[TBL] [Abstract][Full Text] [Related]
15. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
16. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
17. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR
Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800
[TBL] [Abstract][Full Text] [Related]
18. Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on
Job S; Reyniès A; Heller B; Weiss A; Guérin E; Macabre C; Ledrappier S; Bour C; Wasylyk C; Etienne-Selloum N; Brino L; Gaiddon C; Wasylyk B; Jung AC
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181806
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
20. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
